← Leaderboards
Sherif S Farag
Ohio State University
$9,761,380
Attributed
$12,403,002
Total exposure
9
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2005–18$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$12,403,002 · 9
By mechanism
R01$8,264,190 · 3
R21$2,356,310 · 4
P01$1,518,422 · 1
P30$264,080 · 1
Top collaborators
- Hal E. Broxmeyer5 shared
- Louis M Pelus5 shared
Most similar at Ohio State University
Same institution · by research overlap
- Michael A Caligiuri$65,062,344
- Jeffrey John Chalmers$7,748,895
- Chelsea Martin$190,674
- Clara D Bloomfield$12,059,354
- Charles L Shapiro$2,281,818
Others in their field
Top investigators on “Blood”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David R. Weir · University Of Michigan At Ann Arbor$381,545,820
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$292,209,610
- Chanza Baytop · Westat, Inc.$271,217,917
- Mary M Horowitz · Medical College Of Wisconsin$240,114,780
Research focus
BloodBone MarrowCellsCollectionTranslatingBaseClinical ResearchLaboratoriesHematologic NeoplasmsInterestResourcesClinical TrialsClinical DataAcuteSourcePhase Ii Clinical TrialsMolecularPre-ClinicalMalignant NeoplasmsHematopoieticRelapseFutureImmuneHematopoietic Stem Cells
Grant awards (33)
Inhibition of PGE2 for mobilization of autologous peripheral blood stem cells$319,738
R01 · FY2018 · CA · contact PI
Inhibition of PGE2 for mobilization of autologous peripheral blood stem cells$321,933
R01 · FY2017 · CA · contact PI
Enhancing Engraftment of Cord Blood by CD26 Inhibition$720,299
R01 · FY2016 · HL
Inhibition of PGE2 for mobilization of autologous peripheral blood stem cells$321,933
R01 · FY2016 · CA · contact PI
Enhancing Engraftment of Cord Blood by CD26 Inhibition$720,286
R01 · FY2015 · HL
Inhibition of PGE2 for mobilization of autologous peripheral blood stem cells$325,817
R01 · FY2015 · CA · contact PI
Enhancing Engraftment of Cord Blood by CD26 Inhibition$727,047
R01 · FY2014 · HL
Inhibition of PGE2 for mobilization of autologous peripheral blood stem cells$349,482
R01 · FY2014 · CA · contact PI
Enhancing Engraftment of Cord Blood by CD26 Inhibition$716,107
R01 · FY2013 · HL
Enhancing Engraftment of Cord Blood by CD26 Inhibition$760,603
R01 · FY2012 · HL
Multiple kinase target inhibition with EMND-2076 in multiple myeloma$309,964
R21 · FY2011 · CA · contact PI
Pathology$337,691
P01 · FY2010 · CA · contact PI
Multiple kinase target inhibition with EMND-2076 in multiple myeloma$319,550
R21 · FY2010 · CA · contact PI
Pathology$331,401
P01 · FY2009 · CA · contact PI
Leukemia Tissue Bank$69,365
P30 · FY2009 · CA · contact PI
QMS Technology to Deplete T Cell Alloreactivity$588,648
R01 · FY2008 · AI · contact PI
Pathology$321,393
P01 · FY2008 · CA · contact PI
Leukemia Tissue Bank$66,366
P30 · FY2008 · CA · contact PI
QMS Technology to Deplete T Cell Alloreactivity$609,680
R01 · FY2007 · AI · contact PI
Pathology$319,401
P01 · FY2007 · CA · contact PI
Leukemia Tissue Bank$59,639
P30 · FY2007 · CA · contact PI
QMS Technology to Deplete T Cell Alloreactivity$595,781
R01 · FY2006 · AI · contact PI
Pathology$208,536
P01 · FY2006 · CA · contact PI
Leukemia Tissue Bank$34,863
P30 · FY2006 · CA · contact PI
QMS Technology to Deplete T Cell Alloreactivity$599,414
R01 · FY2005 · AI
mTOR Inhibition as a Therapeutic Target in Myeloma$269,100
R21 · FY2005 · CA
Leukemia Tissue Bank$33,847
P30 · FY2005 · CA
QMS Technology to Deplete T Cell Alloreactivity$587,422
R01 · FY2004 · AI
mTOR Inhibition as a Therapeutic Target in Myeloma$269,100
R21 · FY2004 · CA
NK Cell Recognition of Leukemia Blasts and IL-2 Therapy$266,110
R21 · FY2004 · CA
Innate Immune Cell Therapy with Stem Cell Transplants$328,188
R21 · FY2003 · CA
NK Cell Recognition of Leukemia Blasts and IL-2 Therapy$266,110
R21 · FY2003 · CA
Innate Immune Cell Therapy with Stem Cell Transplants$328,188
R21 · FY2002 · CA